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Abstract
Each year approximately 13,000 Veterans transition to maintenance dialysis, mostly in the 
traditional form of thrice-weekly hemodialysis from the start. Among >6,000 dialysis units 
nationwide, there are currently approximately 70 Veterans Affairs (VA) dialysis centers. Given this 
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number of VA dialysis centers and their limited capacity, only 10% of all incident dialysis 
Veterans initiate treatment in a VA center. Evidence suggests that, among Veterans, receipt of care 
within the VA system is associated with favorable outcomes, potentially due to enhanced access to 
healthcare resources. Data from the United States Renal Data System Special Study Center 
“Transition-of-Care-in-CKD” suggest that Veterans who receive dialysis in a VA unit exhibit 
greater survival compared to non-VA centers. Substantial financial expenditures arise from the 
high volume of outsourced care and higher dialysis reimbursement paid by the VA than by 
Medicare to outsourced providers. Given the exceedingly high mortality and abrupt decline in 
residual kidney function (RKF) in the first dialysis year, it is possible that incremental transition to 
dialysis through an initial twice-weekly hemodialysis regimen preserves RKF, prolongs vascular 
access longevity, improves patients’ quality of life, and is a more patient-centered approach and 
consistent with “personalized” dialysis. Broad implementation of incremental dialysis may also 
result in more Veterans receiving care within a VA dialysis unit. Controlled trials are urgently 
needed to examine safety and efficacy of incremental hemodialysis in Veterans and other 
populations, and the administrative and health care as well as provider structure within the VA 
system would facilitate the performance of such trials.
Keywords
Veterans; residual kidney function; twice-weekly hemodialysis; survival; end-stage renal disease
Veterans Heath Care in the United States
The term “Veterans” typically refers to persons who previously served in the armed services. 
According to the United States (US) government, a Veteran is defined as a person who 
served in the active military (army, naval, marine corps, air service, or coast guard) and who 
was discharged or released under conditions other than those that were dishonorable.1 In the 
US, members of the National Guard and Reserve may also qualify as Veterans.1 Whereas 
approximately 90% of the US Veteran population is presently male, it is estimated that in the 
next decade the proportion of females will rise to 18 to 20%.2, 3 Minority Veterans currently 
comprise about 22% of the overall Veterans’ population, among whom the majority are of 
Black or African American race (12% of all Veterans) and Hispanic or Latino ethnicity (7% 
of all veterans).4, 5
While most Veterans are healthy upon joining the armed services due to recruitment 
requirements, some have subsequently been exposed to military or occupational factors, 
including but not limited to participation in combat operations, that later affect their physical 
and mental health with enduring consequences. For instance, Veterans are reported to have a 
higher rate of post-traumatic stress disorder than the general population.6 In order to receive 
federal health care benefits from the Veterans Health Administration (VHA) of the 
Department of Veterans Affairs (VA) including the VA Healthcare System and VA medical 
centers, Veterans must have served a minimum pre-defined period of time and have met 
other qualifications. Services provided by the VHA facilities, which is the nation’s largest 
integrated health care delivery system,7 include comprehensive medical care, life insurance, 
disability compensation, home loans, educational benefits, pensions, and vocational 
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rehabilitation training. In the US, there are more than 20 million living Veterans including 
nine million enrolled in the VHA, among whom roughly six million Veterans receive 
healthcare in the VA Healthcare System.8–10
The VHA facility network consists of approximately 150 medical centers, 820 community-
based outpatient clinics, 300 Veterans’ centers, and 71 dialysis centers. These dialysis 
centers serve Veterans with advanced chronic kidney disease (CKD) whose status is deemed 
as “end-stage renal disease” (ESRD).5
Veterans with Advanced CKD and ESRD
Each year 12,000 to 14,000 Veterans with advanced CKD, i.e., estimated glomerular 
filtration rate (eGFR) <25 ml/min/1.73m2, transition to ESRD to receive renal replacement 
therapy, mostly in the form of maintenance dialysis treatment (see Table 1).9 Hence, 
Veterans comprise 11% of the nation’s incident dialysis population, given that 110,000 to 
120,000 persons initiate maintenance dialysis treatment each year in the US.9, 10 Out of 
450,000 US Americans who currently undergo maintenance dialysis treatment, 
approximately 35,000 or more are Veterans, reflecting a higher ESRD prevalence among 
Veterans than in the general US population (604 vs. 187 per 100,000, respectively).11 The 
majority of these patients undergo thrice-weekly hemodialysis from Day 1 of treatment. The 
vast majority of VA dialysis centers are based in VA hospitals, with the exception of a few 
off-campus dialysis units that have recently been established.12 Hence, the national VA 
dialysis system can be considered a quasi “medium dialysis organization” or chain with a 
somewhat more homogeneous practice pattern. Most of the VA hospital-based dialysis units 
provide both maintenance outpatient and acute inpatient dialysis treatments in the same 
location simultaneously, including dialysis treatment for Veterans with ESRD who are 
admitted to the hospital as well as those with acute kidney injury (AKI) requiring renal 
replacement therapy. To that end, a VA dialysis center is unique, as compared to other non-
VA dialysis clinics where, until December 2016, inpatient dialysis treatments might not be 
performed according to the regulations governed by the Center for Medicare and Medicaid 
Services (CMS).13
The VHA provides comprehensive medical care for patients with kidney disease, including 
all stages of CKD as well as AKI. Any enrolled Veteran who develops ESRD is eligible to 
receive renal replacement therapy from the VHA. Dialysis care is a covered benefit under 
VA’s Medical Benefits Package for Veterans enrolled in the VA, irrespective of their service 
connectedness.13 For patients requiring in-center dialysis treatment, the VHA provides 
dialysis both through units maintained and operated by individual VA facilities (hence 
usually hospital based dialysis centers), or by outsourcing dialysis services to private dialysis 
providers. This may happen in cases where the distance from a VA facility is prohibitive for 
thrice-weekly dialysis therapy, when there is a lack of home dialysis resources or expertise, 
or when the capacity of the VA facility-operated dialysis unit is exceeded.13
Given the relatively small number of VA-based dialysis centers in the nation and their 
limited capacity (each usually has only 10 to 20 dialysis stations), only 10% of all Veterans 
with advanced CKD initiate dialysis treatment in a VA dialysis center, while 90% are receive 
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care in outside (non-VA) dialysis units, some under a subcontracted system. Recent data 
including reports from the United States Renal Data System (USRDS) (see below) suggest 
that Veterans who receive care within a VA dialysis center exhibit greater survival than those 
in non-VA dialysis units.9, 10 Furthermore, substantial financial expenditures arise for 
outsourcing Veterans’ dialysis treatments in non-VA dialysis centers given higher dialysis 
reimbursement paid by the VA than by CMS to non-VA dialysis providers.11 Hence, there 
are compelling reasons to explore effective ways to expand access to and capacity within VA 
dialysis programs to permit more Veterans with ESRD to receive care within the VA 
healthcare system.
Transition of Veterans to Renal Replacement Therapy
In 2014 a new USRDS Special Study Center under the designation “Transition of Care in 
CKD” (TC-CKD) was created to focus on examining patients who transition to renal 
replacement therapy, with special attention to risk factors in the pre-dialysis period. Among 
others, the TC-CKD Special Study Center has examined and annually reported data on all 
Veterans who have transitioned to ESRD starting from the fiscal year 2007 and onwards. 
The initial TC-CKD reports included 52,172 Veterans who transitioned to ESRD over a 
four-year period (10/2007–9/2011) (Table 2).10 Within this cohort, 83% and 78% were 
assigned to in-center hemodialysis on Day 1 and Day 90 of treatment, respectively, while 
those receiving home hemodialysis remained at only 0.5%. Peritoneal dialysis comprised 
5% of the modalities. A total of 589 Veterans (1.1%) received pre-emptive kidney 
transplantation. Most notably, however, 5,348 or 10% of Veterans died in the first 90 days of 
dialysis treatment, translating into an equivalent annualized mortality of 41% in the first 
three months, while 1,798 (3.5%) regained kidney function and stopped dialysis treatment, 
likely after resolution of presumed AKI (see Table 2). The high early dialysis mortality is 
also shown in Figure 1 and discussed further (see below).10
Only 5,157 of these 52,172 Veterans (9.9%) received dialysis therapy in a dialysis unit based 
in a VA Medical Center Table 3; the majority (90%) were outsourced to private dialysis 
providers, including large for-profit dialysis organizations (27.6% and 24.5% of Veterans 
treated within Fresenius and DaVita dialysis units, respectively), other dialysis chains 
(13.1%), or an independent dialysis center (21.1%). After three months of treatment, among 
Veterans continuing to require renal replacement therapy for ESRD, 52.4% still received 
dialysis therapy in a for-profit large dialysis organization, 13.2% in other dialysis chains, 
21.1% in independent (here refed to as “non-chain”) dialysis centers, 2.5% in non-specified 
(unknown) facilities, and 10.7% in VA medical center based dialysis units, suggesting that 
the dialysis provider proportions remain relatively constant over time.
Veterans who received dialysis treatment in a VA medical center were on average five to 
seven years younger than Veterans in non-VA dialysis clinics, such that only 42.4% of the 
former patients were older than 65 years as compared to 64.8% of all Veterans with incident 
ESRD Table 3. VA Medical Centers had a higher prevalence of African Americans (42.6%) 
as compared to all Veterans with incident ESRD (25.9%). Dialysis patients who received 
treatment in a dialysis unit based in a VA hospital exhibited a greater survival at any given 
month over the first 24 months of dialysis initiation or vintage Figure 1. Furthermore, the 
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high early mortality surge notable in the first several months of treatment across all dialysis 
providers is attenuated in VA dialysis units. Preliminary analyses shows that this survival 
superiority of VA dialysis units persists even after multivariate adjustment for case-mix 
characteristics.14
Disparities Among Veterans with Incident ESRD Across the Nation
The TC-CKD Special Study Center chapter in the 2016 USRDS Annual Data Report15 
highlights the characteristics of 85,505 Veterans with incident ESRD who transitioned to 
dialysis over the period of 10/1/2007 to 3/31/2014, i.e., over six-and-a-half years. The 
cohort’s mean ± SD age was 70.1 ± 12.0 years, and included 25% patients of Black race and 
6% of Hispanic ethnicity. The main causes of ESRD were diabetes mellitus (42%) or 
hypertension (31%). Across the nation, the proportion of Black Veterans with incident 
ESRD varied by state and region. Southern states such as Alabama, Georgia, Louisiana, 
Mississippi, and Washington D.C. had the highest prevalences of Black Veterans who 
transitioned to ESRD, whereas northeastern and northwestern states had lower proportions 
Figure 2).15
The national rate of pre-emptive kidney transplantation among Veterans with advanced CKD 
over the same period is described in Figure 3.15 The rates were calculated based on the 
number of pre-emptive transplants divided by the total number of Veterans with incident 
ESRD in that state or territory (n=1,133 pre-emptive transplantations over six-and-a-half 
years in the entire nation). The states with the highest pre-emptive kidney transplantation 
rates among Veterans (>2.1%) were Alaska, Colorado, Delaware, Maryland, Minnesota, 
Montana, New Mexico, Utah, Vermont, and Wyoming. Juxta-positioning these two sets of 
figures highlight potential areas of disparity for pre-emptive kidney transplantation across 
race, implying that there are opportunities to more accurately identify and address the 
discrepancies related to renal replacement therapy modalities and distribution across 
Veterans throughout the nation.
A recent landmark study by Kovesdy et al4 showed that, by having equal access to 
healthcare resources in the VHA system, African Americans have lower all-cause mortality 
and incidence of coronary heart disease as well as a similar incidence of ischemic stroke, 
which stands in contrast to the higher mortality observed among Black individuals in the 
general US population outside of the VA system. Hence, Veterans’ increased opportunity to 
receive dialysis care within an integrated healthcare system could yield improved 
understanding of drivers of disparities in CKD care. In addition, leveraging the VHA’s 
considerable research infrastructure would permit discovery of additional health service 
delivery innovations to reduce disparities and improve outcomes of people with ESRD.
Incremental Dialysis Initiation for Veterans
Whereas prevalent dialysis patients have an exceptionally high mortality rate of 15 to 20% 
per year nationwide, worse than most malignancies,16 mortality is even higher in the first 
several months of dialysis therapy with the annualized mortality surpassing 40% as 
discussed above (see Figure 1 and Table 3). Although a limited number of controlled trials 
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have examined the extent to which clinical outcomes can be improved among prevalent 
dialysis patients, interventions among incident dialysis patients have largely been overlooked 
despite their high mortality, morbidity, and marked decrements in health-related quality of 
life. There is an urgent need to address these crises of care, including the exceptionally high 
death rate of incident dialysis patients. Two potential factors that may be related to high 
early dialysis mortality are (1) loss of residual kidney function and (2) decline in health-
related quality of life, both of which may be direct consequences of abrupt initiation of 
thrice-weekly hemodialysis treatment. It has been suggested, although not unequivocally 
proven, that thrice-weekly or more frequent hemodialysis upon transition to renal 
replacement therapy may accelerate loss of residual kidney function whereas a more gradual 
transition to dialysis, e.g. once to twice-weekly hemodialysis in the first several months of 
dialysis initiation, may preserve residual kidney function. Moreover, a less frequent initial 
hemodialysis schedule may allow patients to more easily adapt to renal replacement therapy 
with less disruption and strain upon their lifestyles. Indeed, residual kidney function and 
elevated health-related quality of life are among the two strongest predictors of survival in 
the first year of dialysis therapy.17
Although not currently the standard of care in the US, there is increasing evidence to suggest 
that initiation of hemodialysis using a twice-weekly schedule may offer substantial benefits, 
even if transition to thrice-weekly hemodialysis is later required.17–19 This incremental 
hemodialysis approach provides a more gradual and tolerable transition to renal replacement 
therapy, thus resulting in better health-related quality of life, longer preservation of the 
residual kidney function,20, 21 reduction of hemodialysis-induced inflammatory and 
oxidative stress,22 decreased frequency of intra-dialytic hypotension, reduced erythropoiesis-
stimulating agent dose, and reduced morbidity and mortality.23, 24 Most importantly, dialysis 
initiation with twice-weekly hemodialysis may be a more patient-centered approach, as it 
may improve quality of life by mitigating interruptions in day-to-day living, employment, 
and relationships; avert post-dialysis fatigue; as well as contain costs. Hence, incremental 
hemodialysis initiation is a more patient-centered approach and consistent with 
“personalized” dialysis, where the provision of renal replacement therapy is based on the 
residual clearance and whole person.
Twice-weekly hemodialysis initiation builds upon the concept of “Incremental Dialysis” 
initially described among peritoneal dialysis patients. In patients who start with peritoneal 
dialysis, residual kidney function is critical to solute clearance, fluid balance, and survival, 
and is preserved by avoiding nephrotoxic agents and by pharmacotherapeutic modulation of 
the renin angiotensin aldosterone pathway.25 Although widely accepted as a treatment 
strategy among peritoneal dialysis patients, the current US paradigm is to initiate “full-
dose,” thrice-weekly hemodialysis therapy without prescription adjustment irrespective of 
presence of residual kidney function and changes over time.
If twice-weekly hemodialysis were to be widely implemented among incident Veterans with 
advanced CKD who are approaching ESRD, it would allow more Veterans to receive care 
that is provided within VA-based dialysis units where Veterans benefit from even greater 
survival (Figure 1 and Table 3). Evidence suggests that over half to two-thirds or more of 
new ESRD patients have adequate residual kidney function for initiation of incremental 
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hemodialysis initiation. According to the 2006 Kidney Disease Outcome Quality Initiative 
dialysis adequacy guidelines, a urea clearance (KRU) greater than 3 ml/min/1.73m2 is 
sufficient for twice-weekly hemodialysis therapy, whereas a decline in KRU to below 2 
ml/min/1.73m2 is suggested as a transition point for increasing frequency to thrice-weekly 
treatment.26 The twice-weekly hemodialysis practice model would allow facilities to start 
three patients on treatment using the same resources that are needed to for two patients on 
thrice-weekly hemodialysis (Figure 4). According to our simulations, if each year 60% of 
the 12,000 to 13,000 Veterans starting thrice-weekly hemodialysis are instead initiated on 
twice-weekly hemodialysis, and assuming that the median time to the needed transition from 
twice-weekly to thrice-weekly HD is nine months based on suggested criteria (Box 1), then 
each year 300 to 500 more Veterans can receive care in a VA based dialysis unit.
Box 1
Proposed Decision Support System with 11 criteria for initiating and 
maintaining incremental (twice-weekly) hemodialysis (HD) treatment upon 
transition to end-stage renal disease (adapted from Kalantar-Zadeh et al.17 
and Rhee et al.33)
Incremental (Twice-Weekly) Hemodialysis Treatment Criteria*
1 Adequate residual kidney function with a urine output >600 ml/day (transition to thrice-weekly if 
urine output drops to <500 ml/day) ‡
2 Limited fluid retention between two consecutive HD treatments with a fluid gain <2.5 kg (or less 
than 5% of the ideal dry weight) without HD for three to four days
3 Limited or readily manageable cardiovascular or pulmonary symptoms without clinically 
significant fluid overload†
4 Suitable body size relative to residual renal function; patients with larger body size may be 
suitable for twice-weekly hemodialysis if not hypercatabolic
5 Hyperkalemia (K >5.5 mEq/L) infrequent or readily manageable
6 Hyperphosphatemia (P >5.5 mg/dL) infrequent or readily manageable
7 Good nutritional status without florid hypercatabolic state
8 Lack of profound anemia (hemoglobin>8 g/dL) and appropriate responsiveness to anemia 
therapy
9 Infrequent hospitalization and easily manageable comorbid conditions
10 Satisfactory health-related quality of life and functional status
11 Residual urea clearance (KRU) >3 ml/min/1.73m2 (transition to thrice-weekly if KRU <2 
ml/min/1.73m2)¶
Implementation Strategies
1 In order to initiate twice-weekly hemodialysis, the patient should meet the first (urine output 
>600 ml/day) and the last criteria (KRU> 3 ml/min/1.73m2)¶, plus most (five out of nine) other 
criteria.
2 Examine these criteria every one to three months in all twice-weekly hemodialysis patients and 
compare outcome measures between twice-weekly and thrice-weekly hemodialysis patients to 
assure outcome non-inferiority for continuation of twice-weekly hemodialysis.
3 Consider transition from a twice-weekly to thrice-weekly hemodialysis regimen if patient’s urine 
output drops <500ml/day, if KRU declines < 2 ml/min/1.73m2, or if patient’s nutritional status or 
general health condition shows a deteriorating trend over time.
*
The proposed criteria may be refined for use in clinical trials and clinical decision making.
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‡
The minimum required urine output to initiate twice-weekly has been changed to 600 ml/day in this 
adaptation, while >500 ml/day is needed to maintain twice-weekly regimen.
†
Lack of systolic dysfunction (EF>40%) and no major coronary intervention over the past three months.
¶Criterion #11 in this adaptation.
For the incremental hemodialysis regimen to be broadly implemented among Veterans, a 
pragmatic randomized controlled trial across multiple VA dialysis centers can be readily 
conducted27 to examine the hypothesis that Veterans who require initiation of maintenance 
dialysis therapy and who have reasonable residual kidney function, i.e., >500 ml/day urine 
output and >3 ml/min1.73m2 urea clearance, twice-weekly incremental hemodialysis during 
the first 12 months of dialysis therapy will slow the rate of residual kidney function decline 
and improve health-related quality of life. Other relevant endpoints to be examined include 
the safety of twice-weekly hemodialysis and its potential benefits including attenuation of 
the very high dialysis mortality in the first several months of dialysis therapy, reduction in 
inflammatory and oxidative stress, enhancement of patient and dialysis staff adherence and 
satisfaction, augmentation of dialysis vascular access longevity, and reduction in the 
hospitalization and readmission risk, as well as other several clinically relevant questions 
such as the roles of loop diuretics administration and avoidance of nephrotoxic agents in 
preserving residual kidney function longer.
How to Implement and Monitor Incremental Hemodialysis
In 2014, the blueprint of a Decision Support System for implementation and monitoring of 
incremental hemodialysis was developed by a group of experts in the setting of a consensus 
article (Box 1).17 This Decision Support System was based on ten clinical metrics to guide 
the initial hemodialysis dose and frequency as well as the transition points for escalation 
from twice-weekly to thrice-weekly hemodialysis, and was tailored for dialysis practice in 
resource limited economies where KRU may not be readily available. In the current review 
paper, we have added KRU (>3 ml/min/1.73m2 to start twice-weekly hemodialysis and < 2 
ml/min/1.73m2 to transition to thrice-weekly hemodialysis) as the 11th metric (see Box 1). 
These metrics should be re-examined in individual patients periodically (e.g. monthly to 
quarterly) to determine the dose and frequency of hemodialysis treatment individually. RKF, 
including the modified urine volume criterion, (>600 ml/day as the minimum urine output to 
consider twice-weekly hemodialysis and <500 ml/day as the transition point for thrice-
weekly hemodialysis) along with the above mentioned KRU threshold levels, is perhaps the 
most important determinant of dialysis dose and frequency.17 The proposed modified 
Decision Support System criteria (Box 1) can be used to this end until the results of 
additional comparative effectiveness studies or randomized controlled trials are available.
How to Reconcile Incremental with Conventional and More Frequent 
Hemodialysis?
There is a general misconception that the objectives of incremental hemodialysis conflicts 
with conventional thrice-weekly and more frequent hemodialysis regimens. Indeed, the 
incremental hemodialysis approach is based on the premise that almost all patients who have 
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initiated renal replacement therapy with a twice-weekly regimen will eventually need to 
transition to thrice-weekly and more frequent hemodialysis schedules given the inevitable 
decline in residual kidney function with the passage of time among most ESRD patients. 
Hence, incremental hemodialysis offers a unique opportunity to expand the spectrum of 
dialysis frequency (leftward on Figure 5) and to better implement individualized or 
personalized dialysis therapy among patients. Traditional and novel urea kinetics models 
with more accurate incorporation of RRF can be employed or developed and evolved to 
more effectively explore as to how incremental versus conventional hemodialysis regimens 
can be evaluated for commensurate urea clearance.28 Given recent data suggesting limited 
reduction in uremic solute concentrations with increased dialysis frequency and time in the 
Frequent Hemodialysis Network Daily Trial,29 more clearance may not necessarily equate 
with more effective uremia management,30. To date there has been no controlled trials of 
incident ESRD patients transitioning to hemodialysis based on the collective of urea kinetics 
of the dialysis therapy and residual kidney function combined.
Veterans’ Preference of Dialysis Treatment
According to some of the coauthors of this and other articles17 who serve as VA staff 
nephrologists, clinicians caring for Veterans with ESRD often encounter patients who 
choose to initiate twice-weekly hemodialysis instead of the routine thrice-weekly protocol as 
their preferance. There are also patients who request once-weekly to twice-weekly 
hemodialysis as a palliative and end-of-life approach as discussed above. Some VA staff 
nephrologists may not object to this arrangement with the caveat that Veterans are clearly 
informed that their choice is not considered conventional.17 Patients may elect less frequent 
dialysis because of reluctance to travel inconvenient distances; skepticism about their need 
for more frequent hemodialysis therapy or any dialysis at all; involvement with ill family 
members and children requiring time and attention; or adverse symptoms related to 
hemodialysis therapy such as post-dialysis fatigue.17 Moreover, some elderly Veterans are 
substantially debilitated, with malignancies or end-stage liver disease and other 
comorbidities, whose quality of life or life expectancy are unlikely to benefit from more 
frequent hemodialysis; these patients are sometimes concerned that more frequent dialysis 
will be aburden on their family members. Hence, many Veterans benefit from having the 
option of twice-weekly hemodialysis both upon initiation of dialysis therapy and discussions 
related to dialysis treatment withdrawal.
Conclusions and Future Steps
The overarching objective of implementing incremental and twice-weekly dialysis 
approaches in the VA dialysis system is to ensure that US Veterans with advanced CKD are 
given the opportunity for expanded choices of renal replacement therapy, especially in the 
first 12 months of their transition to ESRD when mortality is the highest (Figure 1), as well 
as for end-of-life issue considerations (Figure 5). The incremental dialysis approach can 
leverage the existing resources of the VA system under experienced clinicians, researchers, 
and dialysis staff across over 71 VA medical center affiliated dialysis clinics nationwide. 
Thus, based on emerging evidence this innovative and pragmatic dialysis treatment approach 
is posited to improve outcomes of veterans with ESRD, a vulnerable and under-studied 
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population, while helping to overcome existing VA dialysis resource constraints. By 
implementing incremental dialysis, more Veterans with incident ESRD can be retained in 
VA dialysis units (Figure 4), while also potentially improving patients’ outcomes and 
containing excess purchased care costs.
There are other important indications for incremental hemodialysis including gradually 
breaking in new vascular accesses (e.g., arteriovenous fistulas or grafts) to prolong their 
longevity, and to allow Veterans and their families to better adapt physically, mentally, and 
emotionally to a dialysis-dependent lifestyle. It also provides a potential compromise to the 
ongoing debate of early versus later initiation of maintenance dialysis, since it offers an 
alternative to the abrupt transition to conventional thrice-weekly treatments in lieu of the 
traditional all-or-none approach of dialysis therapy.17 It may also allow a more gradual 
escalation from a low protein to high protein diet (for pre-dialysis chronic kidney disease 
and ESRD patients, respectively). Notably, according to an Italian dialysis experience report, 
patients who started dialysis therapy on a once-weekly hemodialysis schedule continued a 
low protein diet on non-dialysis days, while on dialysis days a high protein diet was 
provided.31
We understand that the incremental dialysis approach challenges the current standard of care 
of conventional thrice-weekly hemodialysis. Indeed, it is less likely that the incremental 
dialysis approach will be supported by non-governmental dialysis organizations, given 
perceived reduction in dialysis treatment revenue if twice-weekly hemodialysis is to be 
implemented among most incident dialysis patients. However, the innovative concept of 
incremental hemodialysis may lead to an imminent and more patient-centered paradigm 
shift. We envision that a randomized controlled trial of incremental versus conventional 
thrice-weekly dialysis in VA dialysis centers will examine its safety and efficacy including 
preservation of residual kidney function and improvement in patient-centered outcomes and 
functional status such as health-related quality of life and relevant symptoms related to 
dialysis treatment.32 The ultimate long-term objective is to provide personalized dialysis 
therapy that is tailored to patients’ individual characteristics in order to optimize survival, 
health-related quality of life, and other patient-centered outcomes. The efficient use of 
resources within VA dialysis units are well-suited for timely implementation of a large, 
multi-center controlled trial to address this urgent unmet need in tens of thousands of 
Veterans nationwide and the results could potentially impact millions of people with 
advanced CKD globally.
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Figure 1. 
High mortality rate during the first 12 months of hemodialysis therapy in 52,000 incident 
ESRD Veterans across all states and territories of the United States over four years, i.e., 
10/1/2007–9/30/2011 (adapted from the Transition of Care in Chronic Kidney Disease 
Chapter of the United States Renal Data System 2014/2015 Annual Data Report). 10
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Figure 2. 
Distribution of Black Veterans with incident end-stage renal disease (ESRD) (%) among 
85,505 incident ESRD Veterans across states and territories of the United State over six-and-
half years, i.e., 10/1/2007–3/31/2014 (adapted from Figure 8.1. in Vol 1 of the Transition of 
Care in Chronic Kidney Disease chapter of the 2016/2017 United States Renal Data System 
Annual Data Report).15 The figure depicts states and territories of the United State.
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Figure 3. 
Distribution of pre-emptive kidney transplantation rate among 85,505 incident end-stage 
renal disease (ESRD) Veterans across states and territories of the United States over six-and-
a-half years, i.e., 10/1/2007–3/31/2014 (adapted from Figure 8.3. in Vol 1 of the Transition 
of Care in Chronic Kidney Disease chapter of the 2016/2017 United States Renal Data 
System Annual Data Report).15 The figure depicts states and territories of the United States.
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Figure 4. 
Hemodialysis treatment practice models suggesting that instead of two thrice-weekly 
patients, three twice-weekly patients can be treated using same resources, or as an alternative 
scenario, two twice-weekly patients can allow two extra treatment spots to be available for 
two more frequent (e.g. for two four-times-a-week) hemodialysis patients.
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Figure 5. 
Juxtaposition of conventional (only thrice-weekly) and incremental (with initial twice-
weekly) hemodialysis regimens. The incremental or progressive approach maintains residual 
kidney function (RKF) longer and better integrates the residual urea clearance (KRU), while 
it transitions to more frequent treatment with the decline in RKF over time. Note that a 
palliative or decremental approach is included as an optional scenario for end-of-life 
adjustment, where twice-weekly hemodialysis regimen can be reutilized.
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Table 2
Renal replacement therapy modalities on Days 1, 30, 60 and 90 of end-stage renal disease (ESRD) in 52,172 
Veterans who transitioned to ESRD over a four-year period (from 10/1/207 through 9/30/2011). Adopted from 
the United States Renal Data System 2014/2015 Annual Data Report.10
Dialysis Modality Day 1 Day 30 Day 60 Day 90
In-Center HD 43,242 (83%) 43,244 (83%) 43,149 (83%) 40,905 (78%)
Home HD 260 (0.5%) 260 (0.5%) 259 (0.5%) 258 (0.5%)
CAPD 1,405 (2.7%) 1,405 (2.7%) 1,398 (2.7%) 1,302 (2.5%)
CCPD 1,165 (2.2%) 1,165 (2.2%) 1,173 (2.3%) 1,387 (2.7%)
Other PD 9 (<0.1$) 9 (<0.5%) 9 (<0.1%) 8 (<0.1%)
Uncertain modality 5,301 (10%) 3,509 (6.7%) 626 (1.2%) 460 (0.9%)
Death 201 (0.4%) 1,561 (2.9%) 3,672 (7.1%) 5,348 (10.3%)
Transplant 589 (1.1%) 654 (1.3%) 679 (1.3%) 701 (1.3%)
Loss to follow-up n/a 3 (<0.1%) 3 (<0.1%) 5 (<0.1%)
Recovery of kidney function n/a 362 (0.7%) 1,204 (2.3%) 1,798 (3.5%)
Total N 52,172 52,172 52,172 52,172
Abbreviations:
HD: hemodialysis, PD; peritoneal dialysis; CAPD, chronic ambulatory peritoneal dialysis; CCPD: automated (chronic cyclic) peritoneal dialysis
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